Login
Super Investors Kynam Capital Management, LP
KC

Kynam Capital Management, LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.81B
Positions
34
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (20 quarters reported)

$1.81B $187M
Q4 21 Q4 22 Q4 23 Q4 24 Q4 25 Q3 26

$187M in Q4 2021 → $1.81B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Legend Biotech Corp 10.1% Added 205% 9,154,389 $182M
CT Celldex Therapeutics Inc New 9.1% Trimmed 4.8% 5,066,051 $164M
Syndax Pharmaceuticals Inc 8.5% Added 1.2% 8,150,959 $153M
Vaxcyte Inc 8.2% Trimmed 11% 2,607,964 $148M
VT Viridian Therapeutics Inc 7.0% Trimmed 4.7% 6,148,000 $127M
Cogent Biosciences Inc 6.7% Added 3.4% 3,792,289 $121M
Travere Therapeutics Inc 6.5% Unchanged 2,000,000 $118M
Urogen Pharma Ltd 5.5% Unchanged 2,434,207 $98.9M
VT Vera Therapeutics Inc 5.4% Added 3.8% 3,000,000 $96.9M
Beam Therapeutics Inc 5.3% Added 38% 3,933,894 $96.2M
Cytomx Therapeutics Inc. 3.2% Trimmed 2.6% 21,140,726 $57.5M
Mbx Biosciences Inc 3.0% Unchanged 934,799 $54.8M
Summit Therapeutics Inc 2.8% Added 150% 3,000,000 $50.7M
Relay Therapeutics Inc 2.7% Trimmed 17% 2,751,500 $49.7M
Cullinan Therapeutics Inc 2.6% Unchanged 3,114,132 $47.8M
IH Immunocore Hldgs PLC 2.3% Unchanged 1,375,000 $41.6M
Nurix Therapeutics Inc 1.6% Unchanged 1,194,757 $28.3M
Pharvaris N V 1.4% Added 25% 824,843 $26.2M
Burning Rock Biotech Ltd 1.2% Unchanged 1,238,563 $21.8M
Biocryst Pharmaceuticals Inc 1.2% Unchanged 2,522,660 $21M
Surrozen Inc 0.9% New 486,252 $15.6M
Sutro Biopharma Inc 0.8% Unchanged 872,558 $14.1M
Xenon Pharmaceuticals Inc 0.6% New 280,000 $10.4M
Evommune Inc 0.5% New 1,200,000 $9.91M
Prelude Therapeutics Inc 0.5% Trimmed 4.3% 2,311,955 $9.04M
Geron Corp 0.5% Unchanged 6,836,318 $8.41M
PM Parabilis Medicines Inc 0.4% Unchanged 250,000 $8.07M
Alector Inc 0.4% Added 13% 4,308,494 $7.97M
AP Amarin Corp PLC 0.4% Unchanged 532,982 $6.93M
Harrow Inc 0.2% New 124,655 $3.84M
Caribou Biosciences Inc 0.2% Unchanged 2,503,302 $3.18M
PT Proqr Thrapeutics N V 0.1% Unchanged 1,566,317 $2.6M
Engene Therapeutics Inc 0.1% Unchanged 457,855 $916K
Traws Pharma Inc 0.0% Unchanged 84,400 $50.1K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Legend Biotech Corp Added +6,153,184 +$122M 10.1%
Summit Therapeutics Inc Added +1,800,000 +$30.4M 2.8%
Beam Therapeutics Inc Added +1,093,102 +$26.7M 5.3%
Vaxcyte Inc Trimmed −314,371 −$17.9M 8.2%
Surrozen Inc New +486,252 +$15.6M 0.9%
Insmed Inc Exited −100,000 −$10.7M —
Xenon Pharmaceuticals Inc New +280,000 +$10.4M 0.6%
Evommune Inc New +1,200,000 +$9.91M 0.5%
Relay Therapeutics Inc Trimmed −548,500 −$9.9M 2.7%
CT Celldex Therapeutics Inc New Trimmed −256,857 −$8.32M 9.1%

Showing the 10 largest of 20 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
VT Viridian Therapeutics Inc Added +4,112,225 +$75.5M 6.6%
Legend Biotech Corp Added +1,424,910 +$41.2M 4.8%
Kalvista Pharmaceuticals Inc Exited −1,820,954 −$36.7M —
Relay Therapeutics Inc Added +1,875,741 +$35.1M 3.4%
Apellis Pharmaceuticals Inc Exited −825,000 −$33.2M —
Biocryst Pharmaceuticals Inc Trimmed −3,158,135 −$31.6M 1.4%
Beam Therapeutics Inc Trimmed −841,393 −$28.9M 5.4%
Cytomx Therapeutics Inc. Added +6,690,000 +$25.1M 4.5%
Travere Therapeutics Inc Added +430,982 +$24.5M 6.3%
Travere Therapeutics Inc Exited −800,000 −$23.8M —

Showing the 10 largest of 35 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Cogent Biosciences Inc Trimmed −2,127,892 −$81.9M 9.6%
Tyra Biosciences Inc Exited −1,564,492 −$41.1M —
Urogen Pharma Ltd New +2,247,393 +$40.4M 2.5%
Cg Oncology Inc Exited −945,830 −$39.3M —
Biocryst Pharmaceuticals Inc Trimmed −3,685,731 −$35.1M 3.3%
Travere Therapeutics Inc Added +1,051,134 +$31.2M 2.9%
Beam Therapeutics Inc Added +1,241,971 +$29.6M 5.4%
Legend Biotech Corp New +1,576,295 +$28.5M 1.8%
Cytomx Therapeutics Inc. Added +6,047,016 +$28.4M 4.4%
Beam Therapeutics Inc Exited −937,000 −$26M —

Showing the 10 largest of 33 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
VT Viridian Therapeutics Inc Trimmed −2,957,386 −$92M 2.9%
Cogent Biosciences Inc Trimmed −1,720,949 −$61.1M 14.0%
Cg Oncology Inc Trimmed −1,059,375 −$44M 2.5%
Wave Life Sciences Ltd Trimmed −2,390,948 −$40.6M 2.4%
Mbx Biosciences Inc Trimmed −1,065,201 −$33.6M 1.9%
Engene Holdings Inc Trimmed −3,501,192 −$31.6M 0.9%
VT Vera Therapeutics Inc Trimmed −594,749 −$30.1M 11.1%
Beam Therapeutics Inc New +937,000 +$26M 1.7%
Cytomx Therapeutics Inc Added +5,319,574 +$22.7M 2.4%
Tyra Biosciences Inc Trimmed −765,506 −$20.1M 2.6%

Showing the 10 largest of 39 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Mbx Biosciences Inc New +2,000,000 +$35M 2.6%
UT United Therapeutics Corp Del New +67,588 +$20M 1.5%
Apellis Pharmaceuticals Inc New +808,607 +$18.3M 1.4%
Cg Oncology Inc Trimmed −452,462 −$18.2M 6.0%
VT Vera Therapeutics Inc Added +600,913 +$17.5M 8.7%
Pharvaris N V New +675,000 +$16.8M 1.3%
Travere Therapeutics Inc Trimmed −590,964 −$14.1M 1.7%
Nurix Therapeutics Inc Added +995,000 +$9.19M 1.5%
Urogen Pharma Ltd Trimmed −374,161 −$9.19M 0.5%
Cogent Biosciences Inc Trimmed −606,385 −$8.71M 8.4%

Showing the 10 largest of 17 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Natera Inc Exited −1,167,570 −$165M —
VT Vera Therapeutics Inc Added +1,026,887 +$24.2M 8.7%
IH Immunocore Hldgs PLC Trimmed −719,309 −$22.6M 3.3%
Soleno Therapeutics Inc Exited −302,500 −$21.6M —
Legend Biotech Corp Exited −610,000 −$20.7M —
AP Amarin Corp PLC New +576,111 +$9.34M 1.0%
Urogen Pharma Ltd Added +631,573 +$8.65M 1.0%
CT Celldex Therapeutics Inc New Trimmed −399,271 −$8.13M 13.4%
AP Amarin Corp PLC Exited −12,414,628 −$5.56M —
Liquidia Corporation Trimmed −433,755 −$5.4M 0.3%

Showing the 10 largest of 32 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
SS SPDR S&P 500 ETF Tr Exited −300,000 −$176M —
Natera Inc Trimmed −854,528 −$121M 13.9%
Dynavax Technologies Corp Trimmed −3,940,038 −$51.1M 2.9%
Vaxcyte Inc Added +863,204 +$32.6M 10.2%
CT Celldex Therapeutics Inc New Added +1,435,793 +$26.1M 9.9%
Liquidia Corporation Trimmed −1,632,526 −$24.1M 0.8%
VT Vera Therapeutics Inc Added +942,090 +$22.6M 4.8%
Soleno Therapeutics Inc New +302,500 +$21.6M 1.8%
Legend Biotech Corp New +610,000 +$20.7M 1.7%
VT Viridian Therapeutics Inc Added +1,373,738 +$18.5M 5.3%

Showing the 10 largest of 28 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
SS SPDR S&P 500 ETF Tr New +300,000 +$176M 10.4%
Vaxcyte Inc Added +1,297,508 +$106M 11.3%
CT Celldex Therapeutics Inc New Added +1,605,598 +$40.6M 7.6%
IH Immunocore Hldgs PLC New +1,225,576 +$36.2M 2.1%
Syndax Pharmaceuticals Inc Added +2,677,075 +$35.4M 6.7%
Dynavax Technologies Corp Trimmed −1,771,852 −$22.6M 5.0%
Engene Holdings Inc Added +3,257,863 +$21.7M 2.0%
Cg Oncology Inc Added +748,900 +$21.5M 4.3%
VT Viridian Therapeutics Inc Added +814,967 +$15.6M 3.8%
Cullinan Therapeutics Inc New +1,252,738 +$15.3M 0.9%

Showing the 10 largest of 25 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support